Scientific Reports (Oct 2021)

Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina

  • Chiara Caselli,
  • Raffaele De Caterina,
  • Jeff M Smit,
  • Jonica Campolo,
  • Mohammed El Mahdiui,
  • Rosetta Ragusa,
  • Alberto Clemente,
  • Tiziana Sampietro,
  • Aldo Clerico,
  • Riccardo Liga,
  • Gualtiero Pelosi,
  • Silvia Rocchiccioli,
  • Oberdan Parodi,
  • Arthur Scholte,
  • Jhuani Knuuti,
  • Danilo Neglia,
  • EVINCI and SMARTool

DOI
https://doi.org/10.1038/s41598-021-00020-3
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 12

Abstract

Read online

Abstract We assessed whether high triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) levels, expressed by an increased TG/HDL-C ratio, predict coronary atherosclerotic disease (CAD) outcomes in patients with stable angina. We studied 355 patients (60 ± 9 years, 211 males) with stable angina who underwent coronary computed tomography angiography (CTA), were managed clinically and followed for 4.5 ± 0.9 years. The primary composite outcome was all-cause mortality and non-fatal myocardial infarction. At baseline, the proportion of males, patients with metabolic syndrome, diabetes and obstructive CAD increased across TG/HDL-C ratio quartiles, together with markers of insulin resistance, hepatic and adipose tissue dysfunction and myocardial damage, with no difference in total cholesterol or LDL-C. At follow-up, the global CTA risk score (HR 1.06, 95% confidence interval (CI) 1.03–1.09, P = 0.001) and the IV quartile of the TG/HDL-C ratio (HR 2.85, 95% CI 1.30–6.26, P < 0.01) were the only independent predictors of the primary outcome. The TG/HDL-C ratio and the CTA risk score progressed over time despite increased use of lipid-lowering drugs and reduction in LDL-C. In patients with stable angina, high TG and low HDL-C levels are associated with CAD related outcomes independently of LDL-C and treatments. Trial registration. EVINCI study: ClinicalTrials.gov NCT00979199, registered September 17, 2009; SMARTool study: ClinicalTrials.gov NCT04448691, registered June 26, 2020.